|
Gene: NFKB2 |
Gene summary for NFKB2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | NFKB2 | Gene ID | 4791 |
Gene name | nuclear factor kappa B subunit 2 | |
Gene Alias | CVID10 | |
Cytomap | 10q24.32 | |
Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | Q00653 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4791 | NFKB2 | LZE4T | Human | Esophagus | ESCC | 2.42e-11 | 2.07e-01 | 0.0811 |
4791 | NFKB2 | LZE5T | Human | Esophagus | ESCC | 4.22e-06 | 3.16e-01 | 0.0514 |
4791 | NFKB2 | LZE7T | Human | Esophagus | ESCC | 6.29e-06 | 2.62e-01 | 0.0667 |
4791 | NFKB2 | LZE8T | Human | Esophagus | ESCC | 1.50e-15 | 3.80e-01 | 0.067 |
4791 | NFKB2 | LZE20T | Human | Esophagus | ESCC | 1.23e-02 | 1.03e-01 | 0.0662 |
4791 | NFKB2 | LZE22T | Human | Esophagus | ESCC | 4.32e-05 | 2.90e-01 | 0.068 |
4791 | NFKB2 | LZE24T | Human | Esophagus | ESCC | 1.38e-23 | 7.06e-01 | 0.0596 |
4791 | NFKB2 | LZE21T | Human | Esophagus | ESCC | 9.66e-06 | 4.56e-01 | 0.0655 |
4791 | NFKB2 | LZE6T | Human | Esophagus | ESCC | 1.99e-03 | 1.15e-01 | 0.0845 |
4791 | NFKB2 | P1T-E | Human | Esophagus | ESCC | 3.64e-24 | 9.70e-01 | 0.0875 |
4791 | NFKB2 | P2T-E | Human | Esophagus | ESCC | 5.18e-66 | 1.23e+00 | 0.1177 |
4791 | NFKB2 | P4T-E | Human | Esophagus | ESCC | 6.07e-21 | 3.98e-01 | 0.1323 |
4791 | NFKB2 | P5T-E | Human | Esophagus | ESCC | 1.22e-17 | 3.79e-01 | 0.1327 |
4791 | NFKB2 | P8T-E | Human | Esophagus | ESCC | 1.25e-19 | 4.04e-01 | 0.0889 |
4791 | NFKB2 | P9T-E | Human | Esophagus | ESCC | 6.56e-10 | 1.99e-01 | 0.1131 |
4791 | NFKB2 | P11T-E | Human | Esophagus | ESCC | 2.02e-17 | 6.95e-01 | 0.1426 |
4791 | NFKB2 | P12T-E | Human | Esophagus | ESCC | 3.30e-11 | 2.70e-01 | 0.1122 |
4791 | NFKB2 | P15T-E | Human | Esophagus | ESCC | 6.09e-12 | 3.33e-01 | 0.1149 |
4791 | NFKB2 | P16T-E | Human | Esophagus | ESCC | 1.50e-31 | 6.14e-01 | 0.1153 |
4791 | NFKB2 | P17T-E | Human | Esophagus | ESCC | 3.81e-14 | 6.75e-01 | 0.1278 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000756820 | Esophagus | ESCC | aging | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
GO:00301984 | Esophagus | ESCC | extracellular matrix organization | 171/8552 | 301/18723 | 6.08e-05 | 4.67e-04 | 171 |
GO:00430624 | Esophagus | ESCC | extracellular structure organization | 171/8552 | 302/18723 | 7.73e-05 | 5.76e-04 | 171 |
GO:00452294 | Esophagus | ESCC | external encapsulating structure organization | 172/8552 | 304/18723 | 7.80e-05 | 5.80e-04 | 172 |
GO:003249619 | Esophagus | ESCC | response to lipopolysaccharide | 191/8552 | 343/18723 | 1.11e-04 | 7.73e-04 | 191 |
GO:004851118 | Esophagus | ESCC | rhythmic process | 164/8552 | 298/18723 | 6.80e-04 | 3.57e-03 | 164 |
GO:000223719 | Esophagus | ESCC | response to molecule of bacterial origin | 194/8552 | 363/18723 | 1.64e-03 | 7.61e-03 | 194 |
GO:0002467 | Esophagus | ESCC | germinal center formation | 12/8552 | 14/18723 | 2.51e-03 | 1.08e-02 | 12 |
GO:00380615 | Esophagus | ESCC | NIK/NF-kappaB signaling | 81/8552 | 143/18723 | 5.33e-03 | 2.00e-02 | 81 |
GO:000756812 | Liver | Cirrhotic | aging | 117/4634 | 339/18723 | 3.13e-05 | 3.91e-04 | 117 |
GO:004851111 | Liver | Cirrhotic | rhythmic process | 103/4634 | 298/18723 | 8.47e-05 | 9.19e-04 | 103 |
GO:0038061 | Liver | Cirrhotic | NIK/NF-kappaB signaling | 54/4634 | 143/18723 | 3.64e-04 | 3.07e-03 | 54 |
GO:00324966 | Liver | Cirrhotic | response to lipopolysaccharide | 111/4634 | 343/18723 | 8.15e-04 | 5.95e-03 | 111 |
GO:00022376 | Liver | Cirrhotic | response to molecule of bacterial origin | 113/4634 | 363/18723 | 3.23e-03 | 1.81e-02 | 113 |
GO:000756822 | Liver | HCC | aging | 185/7958 | 339/18723 | 4.28e-06 | 5.50e-05 | 185 |
GO:004851121 | Liver | HCC | rhythmic process | 156/7958 | 298/18723 | 3.54e-04 | 2.46e-03 | 156 |
GO:003249611 | Liver | HCC | response to lipopolysaccharide | 174/7958 | 343/18723 | 1.19e-03 | 6.62e-03 | 174 |
GO:000223711 | Liver | HCC | response to molecule of bacterial origin | 181/7958 | 363/18723 | 2.58e-03 | 1.24e-02 | 181 |
GO:00380611 | Liver | HCC | NIK/NF-kappaB signaling | 77/7958 | 143/18723 | 3.98e-03 | 1.76e-02 | 77 |
GO:000756818 | Oral cavity | OSCC | aging | 194/7305 | 339/18723 | 6.18e-12 | 2.33e-10 | 194 |
Page: 1 2 3 4 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa0520325 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
hsa046259 | Esophagus | ESCC | C-type lectin receptor signaling pathway | 73/4205 | 104/8465 | 1.57e-05 | 7.98e-05 | 4.09e-05 | 73 |
hsa0513428 | Esophagus | ESCC | Legionellosis | 42/4205 | 57/8465 | 1.83e-04 | 6.90e-04 | 3.53e-04 | 42 |
hsa040645 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
hsa05166310 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa0516937 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa0520335 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
hsa0462513 | Esophagus | ESCC | C-type lectin receptor signaling pathway | 73/4205 | 104/8465 | 1.57e-05 | 7.98e-05 | 4.09e-05 | 73 |
hsa0513436 | Esophagus | ESCC | Legionellosis | 42/4205 | 57/8465 | 1.83e-04 | 6.90e-04 | 3.53e-04 | 42 |
hsa0406412 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
hsa0516614 | Liver | Cirrhotic | Human T-cell leukemia virus 1 infection | 87/2530 | 222/8465 | 1.69e-03 | 8.01e-03 | 4.94e-03 | 87 |
hsa0513412 | Liver | Cirrhotic | Legionellosis | 28/2530 | 57/8465 | 1.71e-03 | 8.01e-03 | 4.94e-03 | 28 |
hsa0516914 | Liver | Cirrhotic | Epstein-Barr virus infection | 80/2530 | 202/8465 | 1.80e-03 | 8.33e-03 | 5.13e-03 | 80 |
hsa05203 | Liver | Cirrhotic | Viral carcinogenesis | 76/2530 | 204/8465 | 1.34e-02 | 4.20e-02 | 2.59e-02 | 76 |
hsa0516615 | Liver | Cirrhotic | Human T-cell leukemia virus 1 infection | 87/2530 | 222/8465 | 1.69e-03 | 8.01e-03 | 4.94e-03 | 87 |
hsa0513413 | Liver | Cirrhotic | Legionellosis | 28/2530 | 57/8465 | 1.71e-03 | 8.01e-03 | 4.94e-03 | 28 |
hsa0516915 | Liver | Cirrhotic | Epstein-Barr virus infection | 80/2530 | 202/8465 | 1.80e-03 | 8.33e-03 | 5.13e-03 | 80 |
hsa052031 | Liver | Cirrhotic | Viral carcinogenesis | 76/2530 | 204/8465 | 1.34e-02 | 4.20e-02 | 2.59e-02 | 76 |
Page: 1 2 3 4 5 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NFKB2 | SNV | Missense_Mutation | c.671N>A | p.Gly224Glu | p.G224E | Q00653 | protein_coding | tolerated(0.06) | possibly_damaging(0.875) | TCGA-73-4670-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | SD | |
NFKB2 | SNV | Missense_Mutation | novel | c.1495N>T | p.Gly499Trp | p.G499W | Q00653 | protein_coding | deleterious(0.04) | probably_damaging(0.997) | TCGA-91-6836-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NFKB2 | SNV | Missense_Mutation | novel | c.1106G>C | p.Gly369Ala | p.G369A | Q00653 | protein_coding | tolerated(0.11) | benign(0.003) | TCGA-34-2609-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | gemcitabine | PD |
NFKB2 | SNV | Missense_Mutation | novel | c.1835N>T | p.Ser612Ile | p.S612I | Q00653 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-56-7582-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
NFKB2 | SNV | Missense_Mutation | rs758763622 | c.344N>T | p.Ser115Leu | p.S115L | Q00653 | protein_coding | tolerated(0.07) | benign(0.268) | TCGA-85-7696-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
NFKB2 | SNV | Missense_Mutation | c.2203G>A | p.Asp735Asn | p.D735N | Q00653 | protein_coding | tolerated(0.07) | benign(0.006) | TCGA-CQ-A4CD-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
NFKB2 | SNV | Missense_Mutation | novel | c.833N>T | p.Pro278Leu | p.P278L | Q00653 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-CV-7568-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NFKB2 | SNV | Missense_Mutation | novel | c.2335N>C | p.Glu779Gln | p.E779Q | Q00653 | protein_coding | tolerated(0.3) | benign(0.113) | TCGA-CV-A45Q-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NFKB2 | SNV | Missense_Mutation | novel | c.1540N>A | p.Ala514Thr | p.A514T | Q00653 | protein_coding | tolerated(0.17) | benign(0.202) | TCGA-F7-A624-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
NFKB2 | SNV | Missense_Mutation | novel | c.2053N>T | p.Arg685Cys | p.R685C | Q00653 | protein_coding | deleterious(0.02) | possibly_damaging(0.745) | TCGA-B7-A5TI-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | eloxatin | CR |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4791 | NFKB2 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, KINASE, TRANSCRIPTION FACTOR | Quinoxaline derivative 3 | |||
4791 | NFKB2 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, KINASE, TRANSCRIPTION FACTOR | 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 1 | |||
4791 | NFKB2 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, KINASE, TRANSCRIPTION FACTOR | MD1003 | |||
4791 | NFKB2 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, KINASE, TRANSCRIPTION FACTOR | PG-490-88 | |||
4791 | NFKB2 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, KINASE, TRANSCRIPTION FACTOR | PMID25553724-Compound-US20138552206 5 | |||
4791 | NFKB2 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, KINASE, TRANSCRIPTION FACTOR | CID 867101 | CHEMBL406557 | ||
4791 | NFKB2 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, KINASE, TRANSCRIPTION FACTOR | Edasalonexent | EDASALONEXENT | ||
4791 | NFKB2 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, KINASE, TRANSCRIPTION FACTOR | PMID25553724-Compound-US2011801300410 | |||
4791 | NFKB2 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, KINASE, TRANSCRIPTION FACTOR | N-quinolin-benzene sulphonamide derivative 1 | |||
4791 | NFKB2 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, KINASE, TRANSCRIPTION FACTOR | DNDI1417548 | CHEMBL2094789 |
Page: 1 2 3 4 5 6 7 8 9 10 |